<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Asymptomatic peripheral artery disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Asymptomatic peripheral artery disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Asymptomatic peripheral artery disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark G Davies, MD, PhD, MBA, FACS, FACC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark A Creager, MD, FAHA, FACC, MSVM
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Eidt, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph L Mills, Sr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Collins, MD, PhD, FACS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 07, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3463981735">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Peripheral artery disease (PAD) comes to clinical attention due to reduced blood flow that most commonly affects the lower extremities causing a spectrum of signs and symptoms ranging from discomfort, cramping or pain with ambulation (ie, intermittent claudication), to ischemic rest pain and difficulties with wound healing. However, many individuals who have PAD report few or no classical symptoms, potentially due to functional limitations or adaptation, due to neuropathy, or they may have atypical symptoms that are not recognized as being due to PAD. There is increasing interest in this "asymptomatic" or "subclinical" population, who are typically identified based on an abnormal ankle-brachial index.
        </p>
        <p>
         The prevalence, risk factors, disease progression, and management of individuals with asymptomatic PAD are reviewed. The clinical features and management of symptomatic PAD are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8208.html" rel="external">
          "Clinical features and diagnosis of lower extremity peripheral artery disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8210.html" rel="external">
          "Management of claudication due to peripheral artery disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8215.html" rel="external">
          "Management of chronic limb-threatening ischemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2577312123">
         <span class="h1">
          DEFINITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Asymptomatic PAD is the presence of typical atherosclerotic lesions in the peripheral vasculature that has not been recognized by classical symptomology or functional deficits attributable to those lesions [
         <a href="#rid1">
          1-5
         </a>
         ]. Given the lack of clear-cut symptoms, the diagnosis of asymptomatic PAD is now primarily made based on the presence of appropriate risk factors and an ankle-brachial index (ABI) ≤0.9 obtained for screening or to investigate reduced distal pulses on physical examination. The presence of atherosclerotic lesions seen in imaging studies may also identify the condition. The increasing presence of diabetes and noncompressible vessels further complicates the use of ABI as a diagnostic test for this condition. (See
         <a class="local">
          'Clinical presentations'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Guidelines suggest not obtaining ABI for people with low or no risk for cardiovascular disease [
         <a href="#rid5">
          5-7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15238.html" rel="external">
          "Screening for lower extremity peripheral artery disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For those at moderate-to-high risk for cardiovascular disease, guidelines from the American College of Cardiology and American Heart Association suggest performing ABI to identify PAD. Patients at risk include adults:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         ≥65 years of age
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         ≥50 years of age with other atherosclerotic risk factors or a family history of PAD
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         &lt;50 years of age with diabetes and at least one other atherosclerotic risk factor
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with evidence of atherosclerotic disease in other vascular beds (eg, cerebrovascular, mesenteric), ABI to detect lower extremity PAD should be considered.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other patient groups in whom ABI may be useful include patients with diabetes, chronic renal disease, radiation exposure, posttransplant, and human immunodeficiency virus [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2855910253">
         <span class="h1">
          PREVALENCE AND RISK
         </span>
        </p>
        <p class="headingAnchor" id="H3288146853">
         <span class="h2">
          Prevalence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Estimates of the prevalence of PAD (as defined by ankle-brachial index (ABI) ≤0.9) vary widely [
         <a href="#rid1">
          1,10,11
         </a>
         ]. Some, but not all studies also include ABI &gt;1.4. The clinical subset of asymptomatic PAD represents the largest proportion of patients with PAD [
         <a href="#rid1">
          1,12
         </a>
         ]. For every patient with typical intermittent claudication, there are two to five cases of asymptomatic PAD [
         <a href="#rid13">
          13
         </a>
         ]. A systematic review of screening for PAD in asymptomatic patients reported an overall yield of 17 percent (range 1 to 42 percent) [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         In the Aragon Workers' Health Study (AWHS), which used arterial ultrasound and noncontrast coronary computed tomography (CT), atherosclerotic plaques were seen in 72 percent of the cohort (men 40 to 59 years) [
         <a href="#rid15">
          15
         </a>
         ]. Among nearly 7000 primary care patients 70 years or older or 50 to 69 years with risk factors for atherosclerosis (history of cigarette use or diabetes), PAD was identified in 29 percent; over half of cases were newly diagnosed using the ABI [
         <a href="#rid2">
          2
         </a>
         ]. In the Progression of Early Subclinical Atherosclerosis (PESA) study, subclinical atherosclerosis (defined as the presence of atherosclerotic plaque on imaging) was present in 63 percent of participants (71 percent of males, 48 percent of females); common femoral artery plaque was most common (44 percent) [
         <a href="#rid16">
          16
         </a>
         ]. Most participants with a high Framingham Heart Study (FHS) risk had subclinical disease, but extensive atherosclerosis was also seen in low-risk individuals. In a systematic review, the yield for PAD screening in low-risk populations was 1 to 4 percent [
         <a href="#rid14">
          14
         </a>
         ]. In a study sample of 1017 adults aged 60 to 69 years (average age 66 years) that excluded individuals with major chronic disease but did include smokers and patients with diabetes, the prevalence of PAD was 2 percent, but the prevalence was 6.6 percent in current smokers [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         The PAD Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) program evaluated ABI in 6417 patients 70 years of age or older, or 50 through 69 years of age and a history of cigarette smoking or diabetes [
         <a href="#rid2">
          2
         </a>
         ]. An ABI ≤0.9 identified PAD in 1865 patients (16 percent previously unknown diagnosis). The mean ABI was 0.78 and was similar for those who were newly diagnosed and those who had a prior diagnosis.
        </p>
        <p class="headingAnchor" id="H1478260914">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who develop PAD have well-defined risk factors. The most important risk factors associated with atherosclerosis, in general, include: (See
         <a class="medical medical_review" href="/z/d/html/15210.html" rel="external">
          "Epidemiology, risk factors, and natural history of lower extremity peripheral artery disease", section on 'Epidemiology and risk factors'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increasing age
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cigarette smoking
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diabetes mellitus
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic kidney disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dyslipidemia
        </p>
        <p>
        </p>
        <p>
         The American Heart Association/American College of Cardiology guideline for PAD provided the following age-related associations [
         <a href="#rid18">
          18
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age 65 or older
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age 50 to 64 with risk factors for atherosclerosis (as listed above)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age &lt;50 with diabetes mellitus and one additional risk factor for atherosclerosis (as listed above)
        </p>
        <p>
        </p>
        <p>
         After adjusting for conventional risk factors, low ABI is an independent predictor of cardiovascular risk and may improve traditional methods of cardiovascular risk assessment [
         <a href="#rid4">
          4,14,19-33
         </a>
         ]. In a meta-analysis that included 12 cohort studies with over 57,000 participants, the pooled risk for cardiovascular disease was significantly increased for low versus normal ABI (morbidity: risk ratio [RR] 2.03, 95% CI 1.72-2.41; mortality: RR 2.29, 95% CI 1.98-2.64) [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="local">
          'Risk for cardiovascular events'
         </a>
         below.)
        </p>
        <p>
         Beyond simply using the ABI value, evidence also suggests that functional assessment of walking fitness can help identify those at higher cardiovascular disease risk [
         <a href="#rid34">
          34,35
         </a>
         ]. In one study, poor walking fitness was as strong an independent cardiovascular disease risk factor as smoking and diabetes [
         <a href="#rid35">
          35
         </a>
         ]. Whether walking fitness in part helps identify those with functionally important occult PAD remains unclear.
        </p>
        <p>
         Risk estimation of cardiovascular disease risk can also use multivariable prediction tools (eg, Framingham general risk score (
         <a class="calc calc_professional" href="/z/d/html/13468.html" rel="external">
          calculator 1
         </a>
         and
         <a class="calc calc_professional" href="/z/d/html/13469.html" rel="external">
          calculator 2
         </a>
         ), QRISK). The updated QRISK3 score is a prediction algorithm for cardiovascular disease that uses traditional risk factors (age, systolic blood pressure, smoking status and ratio of total serum cholesterol to high-density lipoprotein cholesterol) together with body mass index, ethnicity, measures of deprivation, family history, chronic kidney disease, rheumatoid arthritis, atrial fibrillation, diabetes mellitus, and antihypertensive treatment [
         <a href="#rid36">
          36
         </a>
         ]. The assessment of cardiovascular risk and risk calculators are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">
          "Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/114029.html" rel="external">
          "Cardiovascular disease risk assessment for primary prevention: Risk calculators"
         </a>
         .)
        </p>
        <p>
         Markers for cardiovascular disease risk include C-reactive protein, apoprotein B, low-density lipoprotein subparticles, homocysteine, and coronary artery calcification [
         <a href="#rid37">
          37,38
         </a>
         ]. Whether walking fitness in part helps identify those with functionally important occult PAD remains unclear. (See
         <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">
          "Overview of established risk factors for cardiovascular disease", section on 'Inflammation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1484.html" rel="external">
          "C-reactive protein in cardiovascular disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4188154038">
         <span class="h2">
          Risk for cardiovascular events
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data support the link between asymptomatic PAD and increased risk for myocardial infarction, stroke, and overall mortality [
         <a href="#rid24">
          24,39,40
         </a>
         ]. The increased risk for death is due to cardiovascular causes but also includes nonvascular etiologies, most of which are neoplasms related to smoking.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular death
         </strong>
         – There may be no difference in mortality for those with asymptomatic compared with symptomatic PAD [
         <a href="#rid22">
          22
         </a>
         ]. Even mildly asymptomatic PAD increases the risk of cardiovascular death [
         <a href="#rid4">
          4,24,28,41,42
         </a>
         ]. A prospective cohort study included 6880 representative unselected patients ≥65 years of age with monitored follow-up over five years [
         <a href="#rid22">
          22
         </a>
         ]. According to physician diagnosis, 5392 patients had no PAD, 836 had asymptomatic PAD (ABI &lt;0.9), and 593 had symptomatic PAD. The risk of death was similar for patients with symptomatic compared with asymptomatic patients with PAD but was significantly higher compared with those without PAD. The event risk was higher for symptomatic compared with asymptomatic patients for the composite of all-cause death or severe vascular event (myocardial infarction, coronary revascularization, stroke, carotid revascularization, or lower-extremity peripheral vascular events; hazard ratio [HR] 1.48, 95% CI 1.21 to 1.80), but not for any revascularization, cardiovascular events alone, or cerebrovascular events alone.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abdominal aortic aneurysm
         </strong>
         – The presence of PAD, even asymptomatic PAD, increased the risk for abdominal aortic aneurysm (AAA) in a prospective study. In the Atherosclerosis Risk in Communities Study (ARIC) study, among 14,148 participants, 530 (3.7 percent) developed incident AAA over a median follow-up of 22.5 years [
         <a href="#rid43">
          43
         </a>
         ]. The risk of incident AAA was increased for symptomatic PAD (HR 4.91, 95% CI 2.88-8.37), and asymptomatic PAD with ABI≤0.9 (HR 2.33, 1.55-3.51), compared with the reference ABI &gt;1.1 to 1.2. Crude 15-year cumulative incidence of AAA in these three groups were 12.3, 3.9, and 1.5 percent, respectively. The associations remained significant after accounting for other potential confounders.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1643001674">
         <span class="h1">
          DISEASE PATTERNS AND ASSOCIATED VASCULAR BEDS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atherosclerosis is systemic disease and as such patients with PAD commonly have atherosclerotic disease in other vascular beds (eg, coronary, carotid, renal, mesenteric). Individuals identified with atherosclerotic disease in any vascular bed have an increased risk for future cardiovascular morbidity and mortality. (See
         <a class="local">
          'Risk for cardiovascular events'
         </a>
         above.)
        </p>
        <p>
         Atherosclerotic disease affects multiple vascular beds (eg, cardiac, cerebrovascular, peripheral, visceral) but tends to be well localized within a particular vascular bed. As with the lower extremity, atherosclerotic disease appears to follow patterns, which may also have a bearing on the natural history and progression of disease and associated end-organ dysfunction. While imaging is not typically necessary or indicated clinically to assess asymptomatic patients (see
         <a class="local">
          'Further evaluation'
         </a>
         below), the following studies demonstrate the general pattern of atherosclerotic disease in low-to-intermediate risk groups.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the PESA study, the presence, distribution, and extent of atherosclerotic lesions was evaluated in 4184 asymptomatic participants aged 40 to 54 years using carotid, abdominal, and iliofemoral artery ultrasound and noncontrast coronary artery CT [
         <a href="#rid16">
          16
         </a>
         ]. Plaques were found in 63 percent of those studied and were most common in the iliofemoral arteries (44 percent), followed by the carotid arteries (31 percent), aorta (25 percent), and coronary arteries (18 percent). Nearly one-half of the participants were classified as having intermediate or generalized disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the AWHS study, atherosclerotic plaques were most common in femoral arteries (54 percent), coronary arteries (38 percent), and carotid arteries (34 percent) [
         <a href="#rid15">
          15
         </a>
         ]. In the AGATHA study, patients with PAD in one vascular bed had a 35 percent chance of having disease in at least one other peripheral territory, and 50 percent had cerebrovascular or coronary artery disease [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of whole body magnetic resonance angiography with contrast among 1531 asymptomatic participants (577 men, median age of cohort 53.5 years) at low-to-intermediate risk for cardiovascular disease, 747 (50 percent) demonstrated disease in one or more vessels [
         <a href="#rid45">
          45
         </a>
         ]. The coronary arteries were not assessed. Vascular stenoses were distributed throughout the body, with approximately 3.5 percent of the arteries in the neck (eg, carotids and vertebrals), torso (eg, abdominal aorta, iliac), and extremities (eg, femoral, popliteal) demonstrating stenoses of &gt;50 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an autopsy study of 121 patients who had no clinical symptoms of PAD prior to their death, advanced plaques (American Heart Association ≥4) were present in 72 percent of common iliac arteries, and were associated with generalized atherosclerosis and cardiovascular disease events [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In a classic review, the natural history of 13,827 patients admitted to a single institution over a 40-year period (1948 to 1983) was reviewed and five major patterns of atherosclerotic disease were identified and classified [
         <a href="#rid47">
          47,48
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type I: The coronary arterial bed (32 percent, mean age 55, 84 percent male)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type II: The major branches of the aortic arch (eg, carotid, subclavian; 17 percent, mean age 62, 65 percent male)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type III: The visceral arterial branches of the abdominal aorta (3 percent, mean age 49.4, 60 percent male)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type IV: The abdominal aorta and lower extremity arteries (42 percent, mean age 59, 80 percent male)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type V: A combination of two or more of these categories occurring simultaneously (6 percent, mean age 61, 73 percent male)
        </p>
        <p>
        </p>
        <p>
         Disease of the aorta and lower extremity arteries were the most prevalent, followed by coronary arteries. By contrast, visceral vessel disease and combined patterns were the least prevalent. Patients initially diagnosed with aortic arch branch disease had a greater tendency to develop disease of the abdominal aorta and lower extremity arteries, and vice versa. In later series, among patients with disease of the aorta and lower extremity arteries, a hemodynamically significant carotid lesion was present in 12 to 25 percent of patients [
         <a href="#rid49">
          49-51
         </a>
         ]. The Atherosclerosis Risk in Communities (ARIC) study [
         <a href="#rid52">
          52
         </a>
         ], and the Edinburgh Artery Study [
         <a href="#rid20">
          20
         </a>
         ], documented an increased risk of stroke in these patients. A separate study of patients with stroke documented an 18.8 percent prevalence of PAD; 60 percent had no lower extremity PAD symptoms [
         <a href="#rid53">
          53
         </a>
         ]. The onset of symptomatic disease and rate of disease progression varied with arterial bed [
         <a href="#rid47">
          47,48
         </a>
         ]. Patients with coronary artery disease and visceral artery disease presented symptomatically at a younger age compared with those in the other categories. More rapid progression of disease was most frequent for aortic arch branch disease and visceral artery disease. Sex did not influence the rate of progression; however, the risk for recurrence or progression of disease in the same category and in a new category was significantly greater in younger patients. In most later studies evaluating the natural progression of disease of the aorta and lower extremities after symptomatic presentation, patients tended to remain stable [
         <a href="#rid54">
          54
         </a>
         ]. Patients who continued to smoke cigarettes and those with diabetes mellitus generally had the highest risk for disease progression.
        </p>
        <p>
         PAD can affect any segment (eg, aortoiliac, femoropopliteal, infrapopliteal) [
         <a href="#rid55">
          55,56
         </a>
         ]. Femoropopliteal disease is the most common anatomic location, occurring in approximately 50 percent in retrospective reviews [
         <a href="#rid57">
          57-59
         </a>
         ]. Patients with aortoiliac disease are likely to have disease involving the femoral and tibial vessels as well. PAD usually occurs in the proximal or mid portions of the arterial segment, but disease can occur more distally. In patients with diabetes, occlusive disease is often localized to the more distal segments of the arterial bed [
         <a href="#rid55">
          55,60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H307063464">
         <span class="h1">
          CLINICAL PRESENTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         PAD not associated with reported symptoms is most often diagnosed because of the finding of an abnormal ankle-brachial index (ABI), or less often, reduced distal pulses on physical examination. Atherosclerosis or arterial calcification might also be detected as an incidental finding on imaging such as plain radiography, duplex ultrasound, or CT [
         <a href="#rid61">
          61-63
         </a>
         ]. It is important to interpret the ABI in the context of the patient's risk factors for atherosclerosis and clinical condition to avoid overlooking symptomatic disease or other conditions. (See
         <a class="local">
          'Evaluate asymptomatic category'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H168299861">
         <span class="h2">
          Abnormal ABI
         </span>
         <span class="headingEndMark">
          —
         </span>
         The report of an abnormal ABI may be the result of screening (eg, self-directed test) evaluation of a patient with known atherosclerosis in another vascular bed, or testing to evaluate an unrelated condition (eg, extremity trauma evaluation). (See
         <a class="medical medical_review" href="/z/d/html/15238.html" rel="external">
          "Screening for lower extremity peripheral artery disease"
         </a>
         .)
        </p>
        <p>
         The ABI is a simple and accurate test for PAD that can be performed in the clinic or at the bedside [
         <a href="#rid6">
          6,64-66
         </a>
         ]. The higher resting systolic blood pressure at the ankle is compared with the higher systolic brachial pressure, and the ratio of the two pressures defines the ABI. An ABI ≤0.9 identifies significant arterial obstruction. (See
         <a class="medical medical_review" href="/z/d/html/8201.html" rel="external">
          "Noninvasive diagnosis of upper and lower extremity arterial disease", section on 'Ankle-brachial index'
         </a>
         .)
        </p>
        <p>
         Some authors have suggested using the lowest ankle pressure for calculating the ABI[
         <a href="#rid17">
          17
         </a>
         ]. For ABI obtained in a clinic setting or at the bedside, multiple measurements may be more useful compared with a single ABI determination [
         <a href="#rid67">
          67
         </a>
         ]. If the examiner is not confident with their measurements or the measurements are inconsistent, the patient can be sent to the vascular laboratory for formal ABI testing.
        </p>
        <p class="headingAnchor" id="H2309896082">
         <span class="h3">
          Interpretation
         </span>
         <span class="headingEndMark">
          —
         </span>
         While the ABI remains an accurate and validated test for arterial obstruction, it is not specific for atherosclerosis as the cause of obstruction. ABI results also need to be interpreted in the light of the patient's functional level. However, atherosclerotic disease is by far the most common cause of arterial obstruction, particularly for lower extremity arterial disease in the context of risk factors for atherosclerosis. (See
         <a class="local">
          'Clinical evaluation'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          False positive: obstruction not due to atherosclerosis
         </strong>
         – Patients with arterial obstruction that is not due to atherosclerotic disease can exhibit a reduced ABI. Some of these conditions occur in younger patients (eg, popliteal entrapment syndrome), which may help to distinguish them from those with PAD. Many of these individuals are asymptomatic. Additional vascular imaging may be warranted for patients with abnormal ABI and other clinical features that suggest nonatherosclerotic vascular disease. (See
         <a class="medical medical_review" href="/z/d/html/15232.html" rel="external">
          "Overview of peripheral vascular problems in athletes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15209.html" rel="external">
          "Nonatheromatous popliteal artery diseases causing claudication or limb-threatening ischemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, other conditions (eg, thrombosed aneurysm, arterial embolism) occur with similar risk factors as PAD. These conditions more often present suddenly with symptoms (eg, acute limb ischemia) or incidentally on imaging studies. (See
         <a class="medical medical_review" href="/z/d/html/8208.html" rel="external">
          "Clinical features and diagnosis of lower extremity peripheral artery disease", section on 'Differential diagnosis of PAD'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          False negative: normal or increased ABI is due to mural calcification
         </strong>
         – Patients with PAD can have an ABI&gt;0.9 [
         <a href="#rid68">
          68
         </a>
         ]. This is more likely to occur with noncompressible arteries, which can lead to a falsely elevated ABI. In these cases, arterial waveforms should be obtained and reviewed to determine if there is PAD present with falsely elevated pressures at rest. A high ABI &gt;1.4 in the context of symptomatic disease is a common finding in patients with diabetes. (See
         <a class="medical medical_review" href="/z/d/html/8201.html" rel="external">
          "Noninvasive diagnosis of upper and lower extremity arterial disease", section on 'High ABI'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1749.html" rel="external">
          "Evaluation of the diabetic foot", section on 'Comprehensive foot examination'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H559832771">
         <span class="h2">
          Incidental imaging finding
         </span>
         <span class="headingEndMark">
          —
         </span>
         With the increasing use of cross-sectional imaging, identification or arterial calcification and atherosclerotic plaque is now more prevalent. This often leads to consultations to a vascular specialist to determine the clinical significance and the need for risk factor modulation.
        </p>
        <p class="headingAnchor" id="H1054661754">
         <span class="h1">
          CLINICAL EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         When a patient presents with a diagnosis of "asymptomatic PAD," it is important to verify the presumed diagnosis by obtaining or verifying the ankle-brachial index (ABI), evaluating the presence of atypical symptoms that would reclassify the patient as having "symptomatic" PAD, and also evaluating the patient's medical history for conditions that reduce their activity level such that symptoms are not likely to be provoked.
        </p>
        <p class="headingAnchor" id="H2365476810">
         <span class="h2">
          Evaluate asymptomatic category
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following categories have been used to describe the types of individuals who may be described as having "asymptomatic" PAD:
        </p>
        <p class="headingAnchor" id="H4109745482">
         <span class="h3">
          Atherosclerotic lesion with no flow reduction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Asymptomatic individuals may have atherosclerotic disease that has not progressed to the extent that blood flow is reduced, and the tissues of the lower extremity remain well perfused at rest and during activity. These patients are truly "asymptomatic" with subclinical atherosclerosis.
        </p>
        <p class="headingAnchor" id="H1094673988">
         <span class="h3">
          Activity level not sufficient to provoke symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Asymptomatic individuals with PAD may have disease that reduces blood flow, and the level of blood flow is sufficient at rest; however, these patients may be more sedentary and the level of their daily activity is insufficient to provoke symptoms [
         <a href="#rid40">
          40
         </a>
         ]. There are many reasons why an individual may be less active including mobility problems (eg, joint disease), systemic illness (eg, cardiomyopathy), neuropathy, and balance issues, among others.
        </p>
        <p>
         Asymptomatic patients who are less physically active are be more likely to develop leg symptoms with provocation [
         <a href="#rid69">
          69
         </a>
         ]. In one study, patients with asymptomatic PAD who did not walk more than six blocks per week were regarded as having "asymptomatic/inactive" PAD, and those who walked more than six blocks per week were classified as having "asymptomatic/active" PAD. Significantly more participants in the asymptomatic/inactive group developed leg pain during a 6-minute walk test compared with those in the asymptomatic/active group (89 versus 33 percent) [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
         Whether clinical manifestations will develop in the future in those with asymptomatic PAD depends upon the location and severity of stenotic lesions, the development of collateral vessels, and changes in the individual's activity level relative to the level of flow reduction. "Inactive" PAD may reflect less cardiovascular reserve that portends a worse overall prognosis compared with individuals with PAD who display symptoms [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3595577174">
         <span class="h3">
          Misinterpreted symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         An individual with PAD may, in fact, be symptomatic. PAD is frequently unrecognized by clinicians and can be overlooked even when the patient has symptoms or symptoms are attributed to another cause [
         <a href="#rid2">
          2,3,70,71
         </a>
         ]. In the lower extremity, one report noted that a classic description of claudication symptoms (ie, exertional extremity pain) was reported in only 32 percent of patients; 48 percent had atypical symptoms [
         <a href="#rid70">
          70
         </a>
         ]. In the PAD Awareness, Risk, and Treatment study, among symptomatic patients, classic claudication was present in &lt;15 percent [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8208.html" rel="external">
          "Clinical features and diagnosis of lower extremity peripheral artery disease", section on 'Atypical extremity pain'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2817066172">
         <span class="h2">
          Evaluate risk for progression
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of progression from asymptomatic lower extremity PAD to ischemic limb symptoms that requires vascular intervention is generally low, but may be underestimated [
         <a href="#rid54">
          54
         </a>
         ]. In a systematic review of observational studies, the cumulative incidence over five years for progression from asymptomatic PAD to intermittent claudication was 7 percent [
         <a href="#rid72">
          72
         </a>
         ]. Increasing age, male sex, smoking, and concurrent cardiovascular disease were all predictors of progression. However, with respect to sex, a population cohort study did not identify any significant differences in the composite risk of major adverse cardiovascular events for females with PAD compared with males, although males may be at increased risk for adverse limb events compared with females [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
         PAD progression as measured by changes in ABI is similar for asymptomatic and symptomatic patients, and while the risk of adverse limb events is less for individuals who are asymptomatic, clinical manifestations can develop or progress rapidly and unpredictably in those with PAD who continue to smoke or those with concomitant diabetes or chronic kidney disease. Progression to chronic limb-threatening ischemia (CLTI) occurs in 1 in 10 patients with established PAD, but is more likely in patients with diabetes [
         <a href="#rid74">
          74,75
         </a>
         ].
        </p>
        <p>
         The decline in ABI closely relates to the baseline value of ABI at the time of initial diagnosis; a more rapid decline in symptomatic patients is seen in patients with lower initial ABI values [
         <a href="#rid23">
          23
         </a>
         ]. One study of 117 patients reported a 30 percent progressive decline in ABI [
         <a href="#rid76">
          76
         </a>
         ]. Other studies have demonstrated a decline in ABI over time that is not necessarily associated with the development of symptoms. On the other hand, the Edinburgh Artery study found no change in ABI over five years in asymptomatic patients [
         <a href="#rid4">
          4
         </a>
         ]. Another study that focused on functional capacity reported a greater decrease over time for those with abnormal ABI, despite a lack of symptoms, compared with those with normal ABI over a two-year time period [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         In the Framingham Heart Study, 381 males and females were followed for 38 years [
         <a href="#rid78">
          78
         </a>
         ]. The risk of developing claudication in asymptomatic patients was increased in patients with elevated serum cholesterol (odds ratio [OR] increase of 1.2 for each 40 mg/dL [1 mmol/L] elevation), cigarette smoking (OR increase 1.4 for each 10 cigarettes smoked per day), moderate hypertension (OR increase 1.5 for mild and 2.2 for moderate hypertension), and diabetes mellitus (OR 2.6) [
         <a href="#rid78">
          78
         </a>
         ]. In patients with diabetes, 28 percent of patients had progression of disease, regardless of symptoms [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         The factors that predicted progression of PAD were evaluated in a longitudinal study of 403 patients using a standard questionnaire, clinical examination, ABI, and the toe-brachial index (TBI) over a mean follow-up of 4.6 years [
         <a href="#rid79">
          79
         </a>
         ]. The following findings were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among patients with follow-up ABI decrements exceeding 0.3 (the study author's definition of progression), significant risk factors after adjustment included: current cigarette smoking (hazard ratio [HR] 3.2, 95% CI 1.51-6.8), ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol (per unit; HR 1.35, 95% CI 1.05-1.73), elevated high-sensitivity C-reactive protein (per 1 mg/L; HR 1.37, 95% CI 0.99-1.90), and elevated lipoprotein(a) (per 1 mg/dL; HR 1.37, 95% CI 1.03-1.82).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertension, triglycerides, homocysteine, and body mass index were not significant for large vessel disease progression as measured by changes in ABI.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diabetes was not cited as a significant factor for large vessel disease progression; however, due to mural calcification leading to varying degrees of noncompressibility, ABI is less accurate in this population. Diabetes was the only significant predictor of progression among patients with a significant decrement in TBI (decrement exceeding 0.27).
        </p>
        <p>
        </p>
        <p>
         Similar findings were noted in the National Health and Nutrition Examination Survey (NHANES) [
         <a href="#rid71">
          71
         </a>
         ] and Multi-Ethnic Study of Atherosclerosis (MESA) studies [
         <a href="#rid80">
          80
         </a>
         ]. In the NHANES study, the risk of PAD was significantly increased in current smokers and patients with diabetes, hypertension, and hyperlipidemia. Other significant risk factors for PAD were decreased renal function and being from a Black population. Each of these factors were also independently predictive of PAD progression, and many had synergistic effects.
        </p>
        <p class="headingAnchor" id="H543497961">
         <span class="h3">
          High-risk for progression
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with early-onset atherosclerosis, diabetes, or end-stage kidney disease have a higher risk for progression of PAD and a worse prognosis.
        </p>
        <p class="headingAnchor" id="H3535829256">
         <span class="h4">
          Early-onset atherosclerosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early-onset or premature atherosclerosis is defined as atherosclerotic associated pathology diagnosed before the age of 50 to 55 years [
         <a href="#rid81">
          81
         </a>
         ]. Patients with early-onset atherosclerosis are more frequently male and are active smokers. Those with PAD more often develop CLTI [
         <a href="#rid82">
          82-86
         </a>
         ]. A defect in coagulation or fibrinolysis is identified in up to 75 percent of patients with early-onset atherosclerosis [
         <a href="#rid87">
          87-89
         </a>
         ]. In one study, 30 percent had hypercoagulable states, and 47 percent had platelet aggregation defects [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
         Outcomes are poor in this group of patients.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One review identified an 8 percent risk of transient ischemic attack, 9 percent risk of stroke, and 60 percent risk of coronary heart disease [
         <a href="#rid90">
          90
         </a>
         ]. Surgery was needed for CLTI in 62 percent of patients, and 38 percent demonstrated further progression of disease following revascularization.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Late amputation rates were significantly higher in a study of patients with early-onset atherosclerosis compared with an older cohort of control patients (17 percent versus 3.9 percent) [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mortality for these younger patients is increased [
         <a href="#rid86">
          86,91
         </a>
         ]. Compared with age-matched controls, patients with early-onset atherosclerosis demonstrate significantly higher mortality (26 versus 1.7 percent) over five years [
         <a href="#rid86">
          86
         </a>
         ]. In one review, 32 percent of younger patients undergoing major amputation died within one year of surgery; 20 percent died within five years [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1023981554">
         <span class="h4">
          Diabetes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diabetes is associated with a higher prevalence of PAD and increased risk for adverse outcomes [
         <a href="#rid92">
          92
         </a>
         ]. In the Prevention Of Progression Of Arterial Disease and Diabetes (POPADAD) trial, 16 percent of 1276 asymptomatic patients with diabetes and PAD (defined as ABI ≤0.99) progressed to intermittent claudication, 3 percent to CLTI, and 1.6 percent to a major amputation at six years [
         <a href="#rid93">
          93
         </a>
         ]. Medical therapies (
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         or antioxidants) had no influence on these numbers. As noted above, in patients with diabetes and PAD, disease is often localized to the more distal portions of the arterial bed [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/17035.html" rel="external">
          "Overview of peripheral artery disease in patients with diabetes mellitus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2123502244">
         <span class="h4">
          Chronic kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         PAD is common among patients with chronic kidney disease (CKD) and is associated with a poor prognosis. Diabetes superimposed on CKD compounds CKD-related PAD. Even mild-to-moderate CKD increases the risk of incident PAD, with a strong association between albuminuria and amputation. Moreover, patients with end-stage kidney disease are at increased risk for vascular calcification, which independently increases the risk of cardiovascular morbidity and mortality.
        </p>
        <p class="headingAnchor" id="H3425433121">
         <span class="h2">
          Further evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Asymptomatic PAD does not require further imaging, and no current guidelines recommend any follow-up. An abnormal ABI is sufficiently accurate for identifying arterial obstruction, such that verifying a diagnosis of PAD in an at-risk asymptomatic patient is generally not necessary.
        </p>
        <p>
         When asymptomatic PAD is diagnosed based on imaging studies, we suggest obtaining an ABI.
        </p>
        <p>
         For patients with identified risk factors and an abnormal ABI, ongoing monitoring of ABI can be incorporated into risk factor modulation and monitoring of medical therapy. It is important to note that some asymptomatic PAD patients, particularly those with diabetes, can develop limb-threatening ischemia without an antecedent history of PAD symptoms. (See
         <a class="local">
          'High-risk for progression'
         </a>
         above.)
        </p>
        <p>
         As discussed above, while the prevalence of atherosclerosis in other vascular beds (eg, coronary, carotid, renal) is higher in patients with asymptomatic PAD compared with those without PAD, there is no evidence to suggest that vascular imaging for atherosclerosis in other arterial beds in the absence of some other clinical suspicion improves clinical outcomes.
        </p>
        <p>
         However, if risk factors are lacking and the clinical features suggest an alternative diagnosis for vascular obstruction, appropriate diagnostic studies should be pursued.
        </p>
        <p class="headingAnchor" id="H620417131">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with asymptomatic PAD, the question arises on whether to institute risk reduction strategies with an aim toward preventing progression and complications, preserving functional status, or reducing the risk for future adverse cardiovascular events [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         <strong>
          Our approach
         </strong>
         – As discussed above, patients with asymptomatic PAD often have known cardiovascular disease affecting other vascular beds and most others have cardiovascular risk factors that would already qualify them for risk reduction strategies. (See
         <a class="local">
          'Evaluate asymptomatic category'
         </a>
         above.)
        </p>
        <p>
         For other individuals with asymptomatic PAD, treatment is individualized accounting for overall cardiovascular risk and weighing the potential risk reduction with potential complications. Our approach to management is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For all patients identified with PAD, including those who have been termed as having asymptomatic PAD, we suggest lifestyle modification and identification and modulation of CV risk factors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with asymptomatic PAD at risk for progression, we suggest the same medical therapies as with symptomatic disease including antiplatelet and statin therapy. This includes patients with diabetes, hypertension, hypercholesterolemia, chronic kidney disease, those who continue smoking and those with early onset atherosclerosis. (See
         <a class="local">
          'Evaluate risk for progression'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H865795765">
         <span class="h2">
          Lifestyle modification
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lifestyle modification includes smoking cessation, exercise, and dietary modification for weight control, as needed. Smoking cessation is recommended for anyone. (See
         <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">
          "Overview of smoking cessation management in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16706.html" rel="external">
          "Benefits and consequences of smoking cessation"
         </a>
         .)
        </p>
        <p>
         Exercise programs can reduce functional impairment for those with asymptomatic PAD. Among 417 individuals with PAD, the annual decline in six-minute walking performance was smaller in a subset of asymptomatic patients who walked for exercise three or more times per week compared with asymptomatic participants who walked fewer than three times per week [
         <a href="#rid94">
          94
         </a>
         ]. In a trial, 882 males with early PAD detected by screening were randomly assigned to "usual care," or a "stop smoking and keep walking" program [
         <a href="#rid95">
          95
         </a>
         ]. At 12 months, more participants in the intervention group improved their maximum walking distance (23 versus 15 percent) and reported walking more than three times per week for recreation (34 versus 25 percent). (See
         <a class="medical medical_review" href="/z/d/html/1510.html" rel="external">
          "Exercise and fitness in the prevention of atherosclerotic cardiovascular disease"
         </a>
         .)
        </p>
        <p>
         Healthy diet and weight control is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/5364.html" rel="external">
          "Healthy diet in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">
          "Obesity in adults: Overview of management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4025958122">
         <span class="h2">
          Potential medical therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Guidelines conflict regarding management of individual identified with asymptomatic PAD [
         <a href="#rid96">
          96
         </a>
         ]. The results of studies specifically looking at outcomes of patients with asymptomatic PAD are reviewed below. Several clinical trials and observational studies of patients with established atherosclerosis, including PAD have shown that medical treatments (eg,
         <a class="drug drug_general" data-topicid="95242" href="/z/d/drug information/95242.html" rel="external">
          vorapaxar
         </a>
         , low dose
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         ,
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , statins,
         <a class="drug drug_general" data-topicid="103780" href="/z/d/drug information/103780.html" rel="external">
          evolocumab
         </a>
         ) reduce adverse limb events. Medical therapies for secondary prevention of cardiovascular disease and outcomes of therapies in patients with symptomatic PAD are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">
          "Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95282.html" rel="external">
          "Overview of lower extremity peripheral artery disease", section on 'Management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3385965905">
         <span class="h3">
          Aspirin
         </span>
         <span class="headingEndMark">
          —
         </span>
         It may be reasonable to treat patients identified with asymptomatic PAD given the systemic nature of atherosclerotic disease and beneficial outcomes in patients with symptomatic PAD [
         <a href="#rid97">
          97-99
         </a>
         ]. The American Heart Association/American College of Cardiology PAD guideline recommends antiplatelet therapy as reasonable if the ankle-brachial index (ABI) is ≤0.9 [
         <a href="#rid18">
          18
         </a>
         ] The European Society of Cardiology guideline recommends against routine antiplatelet therapy in asymptomatic patients [
         <a href="#rid100">
          100
         </a>
         ]. The Society for Vascular Surgery guideline provides no specific recommendation [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">
          "Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"
         </a>
         .)
        </p>
        <p>
         In trials of patients with asymptomatic PAD,
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         compared with placebo did not significantly reduce the incidence of cardiovascular events [
         <a href="#rid93">
          93,101,102
         </a>
         ]. The alternative thresholds used to define PAD in these trials have raised concerns. As such, these neither support nor rule out the efficacy of aspirin in patients with asymptomatic PAD.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A trial in 3350 asymptomatic screened individuals aged 50 to 75 years with an ABI &lt;0.95 (lowest ABI pressure) reported no difference in rates of coronary events, stroke, or revascularization for those randomly assigned to receive
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         100 mg daily or placebo over a mean of 8.2 years [
         <a href="#rid101">
          101
         </a>
         ]. Aspirin was associated with a nonsignificant increased risk of major hemorrhage (hazard ratio 1.71, 95% CI 0.99-2.97).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the Prevention Of Progression of Arterial Disease And Diabetes (POPADAD) trial, 1300 patients with diabetes and asymptomatic PAD (defined as ABI ≤0.99) were randomly assigned to
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         or placebo [
         <a href="#rid93">
          93
         </a>
         ]. The composite endpoint (death from coronary heart disease or stroke, nonfatal myocardial infarction or stroke or major amputation for chronic limb-threatening ischemia) was similar between the groups.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H712856726">
         <span class="h3">
          Statin therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Like
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , statin therapy can be considered in individuals with asymptomatic PAD with risk factors for progression based on the benefits seen in patients with symptomatic PAD, in whom various studies have demonstrated improvements in total and pain-free walking distance [
         <a href="#rid103">
          103-105
         </a>
         ], limb outcomes [
         <a href="#rid106">
          106-108
         </a>
         ], and reduced cardiovascular morbidity and mortality [
         <a href="#rid104">
          104,106,107
         </a>
         ]. Guidelines from the ACCF/American Heart Association PAD and European Society of Cardiology recommend statin therapy [
         <a href="#rid18">
          18,100
         </a>
         ], while the Society for Vascular Surgery provides no specific recommendation [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">
          "Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p>
         The effectiveness of lipid-lowering in patients with asymptomatic PAD has not been addressed in randomized trials [
         <a href="#rid109">
          109
         </a>
         ]. In a retrospective cohort study, patients with an ABI ≤0.95 and individuals without clinically recognized cardiovascular disease were matched 1:1 by inclusion date and propensity score for statin treatment [
         <a href="#rid110">
          110
         </a>
         ]. The matched-pair cohort included 5,480 patients. At a median follow-up of 3.6 years, the incidence of major adverse cardiovascular events was lower for new statin users compared with nonstatin users (19.7 versus 24.7 events per 1,000 person-years, respectively). Total mortality was also lower (24.8 versus 30.3 per 1,000 person-years, respectively).
        </p>
        <p class="headingAnchor" id="H373274447">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117201.html" rel="external">
          "Society guideline links: Occlusive carotid, aortic, renal, mesenteric, and peripheral atherosclerotic disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2658337380">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15738.html" rel="external">
          "Patient education: Peripheral artery disease and claudication (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/3426.html" rel="external">
          "Patient education: Peripheral artery disease and claudication (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H51115723">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asymptomatic PAD
         </strong>
         – Asymptomatic peripheral artery disease (PAD) is defined as the presence of typical atherosclerotic lesions in the peripheral vasculature that has not been recognized by classical symptomology or functional deficits attributable to those lesions. A diagnosis of asymptomatic PAD is primarily made based on the presence of appropriate risk factors and an ankle-brachial index (ABI) ≤0.9 obtained for screening or because of reduced distal pulses on physical examination, but the presence of atherosclerotic lesions seen in imaging studies may also identify the condition. The implications of functional measurement irrespective of the value of an ABI have been raised as a measure of asymptomatic PAD. (See
         <a class="local">
          'Definition'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence and risk for PAD
         </strong>
         – The clinical subset of asymptomatic PAD represents the largest proportion of patients with PAD, with approximately three individuals with asymptomatic PAD for every one individual with symptomatic PAD. Individuals with asymptomatic PAD have an increased risk for future cardiovascular morbidity and mortality. (See
         <a class="local">
          'Prevalence and risk'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Risk factors for PAD include the following risk factors for atherosclerosis (see
         <a class="local">
          'Risk factors'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Increasing age
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cigarette smoking
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diabetes
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chronic kidney disease
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other cardiovascular risk factors such as hypertension, dyslipidemia, and cardiovascular risk equivalents (eg, aneurysmal disease)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Known atherosclerotic disease in the coronary, carotid, renal, visceral, or upper extremity arteries
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age 65 or older
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age 50 to 64 with risk factors for atherosclerosis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age &lt;50 with diabetes mellitus and one additional risk factor for atherosclerosis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical evaluation
         </strong>
         – For patients who are diagnosed with asymptomatic PAD based on an abnormal ABI, it is important to interpret the ABI in the context of the patient's risk factors for atherosclerosis and clinical condition to avoid overlooking symptomatic disease or other conditions. Asymptomatic PAD can be categorized as follows (see
         <a class="local">
          'Clinical evaluation'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          No flow reduction
         </strong>
         – These individuals have atherosclerotic disease, but flow is not reduced. The tissues remain well perfused at rest and during activity. These patients are truly "asymptomatic" with subclinical atherosclerosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Flow reduction but low activity level
         </strong>
         – These individuals have atherosclerotic disease that reduces blood flow, and the tissues of the lower extremity remain well perfused at rest, but the patient has a reduced level of the activity and is unlikely to complain of classical symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Flow reduction and atypical and/or misinterpreted symptoms
         </strong>
         – An individual diagnosed with asymptomatic PAD may, in fact, be symptomatic. Symptoms consistent with PAD can frequently be overlooked or might be attributed to another cause. In the lower extremity, the classic description of claudication symptoms is present in only about one-third of patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease patterns and progression
         </strong>
         – The risk of progression from asymptomatic lower extremity PAD to ischemic limb symptoms that requires vascular intervention is generally low. PAD progression as measured by changes in ABI is similar for asymptomatic and symptomatic patients. The risk of adverse limb events is less for individuals who are asymptomatic, but clinical manifestations can develop or progress rapidly and unpredictably. Risk factors for progression include age, male sex, continued smoking, diabetes, chronic renal disease, and atherosclerotic disease in other vascular beds. (See
         <a class="local">
          'Disease patterns and associated vascular beds'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Patients with asymptomatic PAD often have known cardiovascular disease affecting other vascular beds and most have cardiovascular risk factors that indicate the need for risk reduction strategies. For other individuals with asymptomatic PAD, treatment is individualized accounting for overall cardiovascular risk and weighing the potential benefits of risk reduction with potential complications. Treatment aims to prevent PAD progression and complications, preserve functional status, and reduce the risk for future adverse cardiovascular events. Our approach to management is as follows (see
         <a class="local">
          'Management'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lifestyle modification is recommended for all patients with atherosclerosis and includes smoking cessation, exercise, and dietary modification for weight control, as needed. (See
         <a class="local">
          'Lifestyle modification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with asymptomatic PAD at risk for progression are appropriate for all interventions recommended for patients with established cardiovascular disease including
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and statin therapy. This includes patients with diabetes, hypertension, hypercholesterolemia, chronic kidney disease, early onset atherosclerosis, and those who continue to smoke. (See
         <a class="local">
          'Evaluate risk for progression'
         </a>
         above and
         <a class="local">
          'Potential medical therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Criqui MH, Matsushita K, Aboyans V, et al. Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association. Circulation 2021; 144:e171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 2004; 172:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowkes FG, Housley E, Cawood EH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Conte MS, Pomposelli FB, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg 2015; 61:2S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guirguis-Blake JM, Evans CV, Redmond N, Lin JS. Screening for Peripheral Artery Disease Using the Ankle-Brachial Index: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2018; 320:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           US Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for Peripheral Artery Disease and Cardiovascular Disease Risk Assessment With the Ankle-Brachial Index: US Preventive Services Task Force Recommendation Statement. JAMA 2018; 320:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valdivielso JM, Rodríguez-Puyol D, Pascual J, et al. Atherosclerosis in Chronic Kidney Disease: More, Less, or Just Different? Arterioscler Thromb Vasc Biol 2019; 39:1938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jenkins A, Januszewski A, O'Neal D. The early detection of atherosclerosis in type 1 diabetes: why, how and what to do about it. Cardiovasc Endocrinol Metab 2019; 8:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation 2011; 124:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sigvant B, Wiberg-Hedman K, Bergqvist D, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg 2007; 45:1185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Behroozian AA, Beckman JA. Asymptomatic peripheral artery disease: Silent but deadly. Prog Cardiovasc Dis 2021; 65:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015; 116:1509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alahdab F, Wang AT, Elraiyah TA, et al. A systematic review for the screening for peripheral arterial disease in asymptomatic patients. J Vasc Surg 2015; 61:42S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laclaustra M, Casasnovas JA, Fernández-Ortiz A, et al. Femoral and Carotid Subclinical Atherosclerosis Association With Risk Factors and Coronary Calcium: The AWHS Study. J Am Coll Cardiol 2016; 67:1263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-Friera L, Peñalvo JL, Fernández-Ortiz A, et al. Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study. Circulation 2015; 131:2104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor-Piliae RE, Fair JM, Varady AN, et al. Ankle brachial index screening in asymptomatic older adults. Am Heart J 2011; 161:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017; 135:e726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996; 25:1172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bundó M, Muñoz L, Pérez C, et al. Asymptomatic peripheral arterial disease in type 2 diabetes patients: a 10-year follow-up study of the utility of the ankle brachial index as a prognostic marker of cardiovascular disease. Ann Vasc Surg 2010; 24:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diehm C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation 2009; 120:2053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicoloff AD, Taylor LM Jr, Sexton GJ, et al. Relationship between site of initial symptoms and subsequent progression of disease in a prospective study of atherosclerosis progression in patients receiving long-term treatment for symptomatic peripheral arterial disease. J Vasc Surg 2002; 35:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008; 300:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forés R, Alzamora MT, Pera G, et al. Contribution of the ankle-brachial index to improve the prediction of coronary risk: The ARTPER cohort. PLoS One 2018; 13:e0191283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindholt JS, Søgaard R. Population screening and intervention for vascular disease in Danish men (VIVA): a randomised controlled trial. Lancet 2017; 390:2256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindholt JS, Søgaard R, Rasmussen LM, et al. Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial. N Engl J Med 2022; 387:1385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AJ, Price JF, Russell MJ, et al. Improved prediction of fatal myocardial infarction using the ankle brachial index in addition to conventional risk factors: the Edinburgh Artery Study. Circulation 2004; 110:3075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang J, Sun H, Yang X, et al. Dose-Response Association of Low and Normal Ankle Brachial Index With the Risk of Cardiovascular Disease Morbidity and Mortality. Angiology 2023; 74:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murabito JM, Evans JC, Nieto K, et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002; 143:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leng GC, Fowkes FG, Lee AJ, et al. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ 1996; 313:1440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos R, Quesada M, Solanas P, et al. Prevalence of symptomatic and asymptomatic peripheral arterial disease and the value of the ankle-brachial index to stratify cardiovascular risk. Eur J Vasc Endovasc Surg 2009; 38:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Kuijk JP, Flu WJ, Bax JJ, Poldermans D. Prevalence of (a)symptomatic peripheral arterial disease; the additional value of ankle-brachial index on cardiovascular risk stratification. Eur J Vasc Endovasc Surg 2009; 38:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mora S, Redberg RF, Cui Y, et al. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. JAMA 2003; 290:1600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wei M, Kampert JB, Barlow CE, et al. Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men. JAMA 1999; 282:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017; 357:j2099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saenz-Pipaon G, Martinez-Aguilar E, Orbe J, et al. The Role of Circulating Biomarkers in Peripheral Arterial Disease. Int J Mol Sci 2021; 22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di X, Han W, Liu CW, et al. A systematic review and meta-analysis on the association between C-reactive protein levels and adverse limb events after revascularization in patients with peripheral arterial disease. J Vasc Surg 2021; 74:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hooi JD, Kester AD, Stoffers HE, et al. Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study. J Clin Epidemiol 2004; 57:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDermott MM, Guralnik JM, Ferrucci L, et al. Asymptomatic peripheral arterial disease is associated with more adverse lower extremity characteristics than intermittent claudication. Circulation 2008; 117:2484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doobay AV, Anand SS. Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review. Arterioscler Thromb Vasc Biol 2005; 25:1463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Hare AM, Katz R, Shlipak MG, et al. Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study. Circulation 2006; 113:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hicks CW, Al-Qunaibet A, Ding N, et al. Symptomatic and asymptomatic peripheral artery disease and the risk of abdominal aortic aneurysm: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2021; 333:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowkes FG, Low LP, Tuta S, et al. Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study. Eur Heart J 2006; 27:1861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lambert MA, Weir-McCall JR, Salsano M, et al. Prevalence and Distribution of Atherosclerosis in a Low- to Intermediate-Risk Population: Assessment with Whole-Body MR Angiography. Radiology 2018; 287:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakamura E, Sato Y, Iwakiri T, et al. Asymptomatic Plaques of Lower Peripheral Arteries and Their Association with Cardiovascular Disease: An Autopsy Study. J Atheroscler Thromb 2017; 24:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeBakey ME, Lawrie GM, Glaeser DH. Patterns of atherosclerosis and their surgical significance. Ann Surg 1985; 201:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeBakey ME, Glaeser DH. Patterns of atherosclerosis: effect of risk factors on recurrence and survival-analysis of 11,890 cases with more than 25-year follow-up. Am J Cardiol 2000; 85:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klop RB, Eikelboom BC, Taks AC. Screening of the internal carotid arteries in patients with peripheral vascular disease by colour-flow duplex scanning. Eur J Vasc Surg 1991; 5:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexandrova NA, Gibson WC, Norris JW, Maggisano R. Carotid artery stenosis in peripheral vascular disease. J Vasc Surg 1996; 23:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng SW, Wu LL, Ting AC, et al. Screening for asymptomatic carotid stenosis in patients with peripheral vascular disease: a prospective study and risk factor analysis. Cardiovasc Surg 1999; 7:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng ZJ, Sharrett AR, Chambless LE, et al. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 1997; 131:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoshino H, Itoh Y, Yamada S, Suzuki N. Prevalence and clinical features of asymptomatic peripheral artery disease in Japanese stroke patients. J Stroke Cerebrovasc Dis 2013; 22:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohler ER 3rd, Bundens W, Denenberg J, et al. Progression of asymptomatic peripheral artery disease over 1 year. Vasc Med 2012; 17:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mills JL. Lower limb ischaemia in patients with diabetic foot ulcers and gangrene: recognition, anatomic patterns and revascularization strategies. Diabetes Metab Res Rev 2016; 32 Suppl 1:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen Q, Shi Y, Wang Y, Li X. Patterns of disease distribution of lower extremity peripheral arterial disease. Angiology 2015; 66:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diehm N, Shang A, Silvestro A, et al. Association of cardiovascular risk factors with pattern of lower limb atherosclerosis in 2659 patients undergoing angioplasty. Eur J Vasc Endovasc Surg 2006; 31:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haltmayer M, Mueller T, Horvath W, et al. Impact of atherosclerotic risk factors on the anatomical distribution of peripheral arterial disease. Int Angiol 2001; 20:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogt MT, Wolfson SK, Kuller LH. Segmental arterial disease in the lower extremities: correlates of disease and relationship to mortality. J Clin Epidemiol 1993; 46:1267.
          </a>
         </li>
         <li class="breakAll">
          Hardman RL, Jazaeri O, Yi J, et al. Overview of classification systems in peripheral artery disease. In: Seminars in interventional radiology, 4, Thieme Medical Publishers, 2014. Vol 31, p.378.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faltado AL Jr, Sandoval MAS, Kaw L. Peripheral arterial disease as seen on X-ray and arteriography. BMJ Case Rep 2017; 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Ascenzo F, Cerrato E, Calcagno A, et al. High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis. Atherosclerosis 2015; 240:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suh B, Song YS, Shin DW, et al. Incidentally detected atherosclerosis in the abdominal aorta or its major branches on computed tomography is highly associated with coronary heart disease in asymptomatic adults. J Cardiovasc Comput Tomogr 2018; 12:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aboyans V, Criqui MH, Abraham P, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation 2012; 126:2890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Rev Esp Cardiol (Engl Ed) 2018; 71:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017; 69:1465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fook TJ, Ranadive NS, Basu PK. The prevention of autolysis of stored cornea using steroid as a lysosome membrane stabilizer. Can J Ophthalmol 1975; 10:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nam SC, Han SH, Lim SH, et al. Factors affecting the validity of ankle-brachial index in the diagnosis of peripheral arterial obstructive disease. Angiology 2010; 61:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDermott MM. Lower extremity manifestations of peripheral artery disease: the pathophysiologic and functional implications of leg ischemia. Circ Res 2015; 116:1540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001; 286:1599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004; 110:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sigvant B, Lundin F, Wahlberg E. The Risk of Disease Progression in Peripheral Arterial Disease is Higher than Expected: A Meta-Analysis of Mortality and Disease Progression in Peripheral Arterial Disease. Eur J Vasc Endovasc Surg 2016; 51:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hussain MA, Lindsay TF, Mamdani M, et al. Sex differences in the outcomes of peripheral arterial disease: a population-based cohort study. CMAJ Open 2016; 4:E124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA 2006; 295:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nehler MR, Duval S, Diao L, et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. J Vasc Surg 2014; 60:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leibson CL, Ransom JE, Olson W, et al. Peripheral arterial disease, diabetes, and mortality. Diabetes Care 2004; 27:2843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDermott MM, Greenland P, Liu K, et al. Sex differences in peripheral arterial disease: leg symptoms and physical functioning. J Am Geriatr Soc 2003; 51:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997; 96:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aboyans V, Criqui MH, Denenberg JO, et al. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 2006; 113:2623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allison MA, Cushman M, Solomon C, et al. Ethnicity and risk factors for change in the ankle-brachial index: the Multi-Ethnic Study of Atherosclerosis. J Vasc Surg 2009; 50:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neifert AR, Su D, Ochoa Chaar CI, Sumpio BE. Premature atherosclerosis: A review of current literature. J Vasc Surg Vascular Insights 2023; 1:100013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maillet A, Desormais I, Rivière AB, et al. Peripheral Atheromatous Arterial Disease in the Young: Risk Factors, Clinical Features, and Prognosis From the COPART Cohort. Angiology 2017; 68:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta A, Dhindsa DS, Hooda A, et al. Premature atherosclerotic peripheral artery disease: An underrecognized and undertreated disorder with a rising global prevalence. Trends Cardiovasc Med 2021; 31:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esteghamat F, Broughton JS, Smith E, et al. CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation. Nat Genet 2019; 51:1233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barretto S, Ballman KV, Rooke TW, Kullo IJ. Early-onset peripheral arterial occlusive disease: clinical features and determinants of disease severity and location. Vasc Med 2003; 8:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris LM, Peer R, Curl GR, et al. Long-term follow-up of patients with early atherosclerosis. J Vasc Surg 1996; 23:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eldrup-Jorgensen J, Flanigan DP, Brace L, et al. Hypercoagulable states and lower limb ischemia in young adults. J Vasc Surg 1989; 9:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aronson DC, Ruys T, van Bockel JH, et al. A prospective survey of risk factors in young adults with arterial occlusive disease. Eur J Vasc Surg 1989; 3:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson EJ, Prentice CR, Parapia LA. Premature arterial disease associated with familial antithrombin III deficiency. Thromb Haemost 1990; 63:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valentine RJ, Myers SI, Inman MH, et al. Late outcome of amputees with premature atherosclerosis. Surgery 1996; 119:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansen ME, Valentine RJ, McIntire DD, et al. Age-related differences in the distribution of peripheral atherosclerosis: when is atherosclerosis truly premature? Surgery 1995; 118:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Britton KA, Mukamal KJ, Ix JH, et al. Insulin resistance and incident peripheral artery disease in the Cardiovascular Health Study. Vasc Med 2012; 17:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337:a1840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDermott MM, Liu K, Ferrucci L, et al. Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more. Ann Intern Med 2006; 144:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler B, Jamrozik K, Norman P, et al. Improving maximum walking distance in early peripheral arterial disease: randomised controlled trial. Aust J Physiother 2002; 48:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen Q, Li L, Chen Q, et al. Critical appraisal of international guidelines for the screening and treatment of asymptomatic peripheral artery disease: a systematic review. BMC Cardiovasc Disord 2019; 19:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009; 301:1909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Critical Leg Ischaemia Prevention Study (CLIPS) Group, Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 2007; 261:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong PF, Chong LY, Mikhailidis DP, et al. Antiplatelet agents for intermittent claudication. Cochrane Database Syst Rev 2011; :CD001272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           European Stroke Organisation, Tendera M, Aboyans V, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:2851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambler GK, Waldron CA, Contractor UB, et al. Umbrella review and meta-analysis of antiplatelet therapy for peripheral artery disease. Br J Surg 2020; 107:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003; 108:1481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aung PP, Maxwell HG, Jepson RG, et al. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev 2007; :CD000123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDermott MM, Guralnik JM, Greenland P, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 2003; 107:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sagris M, Katsaros I, Giannopoulos S, et al. Statins and statin intensity in peripheral artery disease. Vasa 2022; 51:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arya S, Khakharia A, Binney ZO, et al. Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease. Circulation 2018; 137:1435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumbhani DJ, Steg PG, Cannon CP, et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J 2014; 35:2864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos R, García-Gil M, Comas-Cufí M, et al. Statins for Prevention of Cardiovascular Events in a Low-Risk Population With Low Ankle Brachial Index. J Am Coll Cardiol 2016; 67:630.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 129297 Version 3.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34315230" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11560536" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Peripheral arterial disease detection, awareness, and treatment in primary care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14709362" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1917239" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25638515" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29998343" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Screening for Peripheral Artery Disease Using the Ankle-Brachial Index: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29998344" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Screening for Peripheral Artery Disease and Cardiovascular Disease Risk Assessment With the Ankle-Brachial Index: US Preventive Services Task Force Recommendation Statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31412740" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Atherosclerosis in Chronic Kidney Disease: More, Less, or Just Different?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31646294" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The early detection of atherosclerosis in type 1 diabetes: why, how and what to do about it.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21690489" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17543683" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33617896" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Asymptomatic peripheral artery disease: Silent but deadly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25908725" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Epidemiology of peripheral artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25721066" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : A systematic review for the screening for peripheral arterial disease in asymptomatic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26988945" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Femoral and Carotid Subclinical Atherosclerosis Association With Risk Factors and Coronary Calcium: The AWHS Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25882487" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21570532" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Ankle brachial index screening in asymptomatic older adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27840333" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1729621" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Mortality over a period of 10 years in patients with peripheral arterial disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9027521" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21035692" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Asymptomatic peripheral arterial disease in type 2 diabetes patients: a 10-year follow-up study of the utility of the ankle brachial index as a prognostic marker of cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19901192" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11802131" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Relationship between site of initial symptoms and subsequent progression of disease in a prospective study of atherosclerosis progression in patients receiving long-term treatment for symptomatic peripheral arterial disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18612117" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29338049" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Contribution of the ankle-brachial index to improve the prediction of coronary risk: The ARTPER cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28859943" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Population screening and intervention for vascular disease in Danish men (VIVA): a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36027560" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15477416" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Improved prediction of fatal myocardial infarction using the ankle brachial index in addition to conventional risk factors: the Edinburgh Artery Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35830466" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Dose-Response Association of Low and Normal Ankle Brachial Index With the Risk of Cardiovascular Disease Morbidity and Mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12075249" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8973232" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19515589" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Prevalence of symptomatic and asymptomatic peripheral arterial disease and the value of the ankle-brachial index to stratify cardiovascular risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19524459" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Prevalence of (a)symptomatic peripheral arterial disease; the additional value of ankle-brachial index on cardiovascular risk stratification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14506119" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10546694" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28536104" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33808453" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The Role of Circulating Biomarkers in Peripheral Arterial Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33684473" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : A systematic review and meta-analysis on the association between C-reactive protein levels and adverse limb events after revascularization in patients with peripheral arterial disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15066690" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18458172" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Asymptomatic peripheral arterial disease is associated with more adverse lower extremity characteristics than intermittent claudication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15879302" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16432070" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34419824" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Symptomatic and asymptomatic peripheral artery disease and the risk of abdominal aortic aneurysm: The Atherosclerosis Risk in Communities (ARIC) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16820367" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29714681" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Prevalence and Distribution of Atherosclerosis in a Low- to Intermediate-Risk Population: Assessment with Whole-Body MR Angiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28367862" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Asymptomatic Plaques of Lower Peripheral Arteries and Their Association with Cardiovascular Disease: An Autopsy Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3155934" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Patterns of atherosclerosis and their surgical significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10781750" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Patterns of atherosclerosis: effect of risk factors on recurrence and survival-analysis of 11,890 cases with more than 25-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2009983" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Screening of the internal carotid arteries in patients with peripheral vascular disease by colour-flow duplex scanning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8627901" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Carotid artery stenosis in peripheral vascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10386747" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Screening for asymptomatic carotid stenosis in patients with peripheral vascular disease: a prospective study and risk factor analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9180252" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22000526" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Prevalence and clinical features of asymptomatic peripheral artery disease in Japanese stroke patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22363014" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Progression of asymptomatic peripheral artery disease over 1 year.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26455728" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Lower limb ischaemia in patients with diabetic foot ulcers and gangrene: recognition, anatomic patterns and revascularization strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24650949" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Patterns of disease distribution of lower extremity peripheral arterial disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16269257" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Association of cardiovascular risk factors with pattern of lower limb atherosclerosis in 2659 patients undergoing angioplasty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11573053" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Impact of atherosclerotic risk factors on the anatomical distribution of peripheral arterial disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8229104" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Segmental arterial disease in the lower extremities: correlates of disease and relationship to mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8229104" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Segmental arterial disease in the lower extremities: correlates of disease and relationship to mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29141927" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Peripheral arterial disease as seen on X-ray and arteriography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25797313" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29573979" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Incidentally detected atherosclerosis in the abdominal aorta or its major branches on computed tomography is highly associated with coronary heart disease in asymptomatic adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23159553" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29425606" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27851991" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/133" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : The prevention of autolysis of stored cornea using steroid as a lysosome membrane stabilizer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19759029" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Factors affecting the validity of ankle-brachial index in the diagnosis of peripheral arterial obstructive disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25908727" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Lower extremity manifestations of peripheral artery disease: the pathophysiologic and functional implications of leg ischemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11585483" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15262830" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26777541" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The Risk of Disease Progression in Peripheral Arterial Disease is Higher than Expected: A Meta-Analysis of Mortality and Disease Progression in Peripheral Arterial Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27280110" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Sex differences in the outcomes of peripheral arterial disease: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16449620" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Medical treatment of peripheral arterial disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24820900" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15562195" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Peripheral arterial disease, diabetes, and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12558719" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Sex differences in peripheral arterial disease: leg symptoms and physical functioning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9236415" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Intermittent claudication. A risk profile from The Framingham Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16735675" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Risk factors for progression of peripheral arterial disease in large and small vessels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19628357" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Ethnicity and risk factors for change in the ankle-brachial index: the Multi-Ethnic Study of Atherosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Premature atherosclerosis: A review of current literature
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28782991" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Peripheral Atheromatous Arterial Disease in the Young: Risk Factors, Clinical Features, and Prognosis From the COPART Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32565142" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Premature atherosclerotic peripheral artery disease: An underrecognized and undertreated disorder with a rising global prevalence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31358993" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14518611" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Early-onset peripheral arterial occlusive disease: clinical features and determinants of disease severity and location.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8627891" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Long-term follow-up of patients with early atherosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2521908" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Hypercoagulable states and lower limb ischemia in young adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2744153" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : A prospective survey of risk factors in young adults with arterial occlusive disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2339350" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Premature arterial disease associated with familial antithrombin III deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8619201" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Late outcome of amputees with premature atherosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7482270" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Age-related differences in the distribution of peripheral atherosclerosis: when is atherosclerosis truly premature?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22402937" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Insulin resistance and incident peripheral artery disease in the Cardiovascular Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18927173" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16389250" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12443521" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Improving maximum walking distance in early peripheral arterial disease: randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30646843" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Critical appraisal of international guidelines for the screening and treatment of asymptomatic peripheral artery disease: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19436018" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17305650" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22071801" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Antiplatelet agents for intermittent claudication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21873417" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20197530" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31808552" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Umbrella review and meta-analysis of antiplatelet therapy for peripheral artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12952839" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17943736" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Lipid-lowering for peripheral arterial disease of the lower limb.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12578881" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35673949" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Statins and statin intensity in peripheral artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29330214" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24585266" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12114036" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26868687" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Statins for Prevention of Cardiovascular Events in a Low-Risk Population With Low Ankle Brachial Index.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
